ALBANY, N.Y., Sept. 3, 2015 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) is pleased to announce that it has appointed Christopher Conway as Senior Vice President of
Discovery and Development and Global Commercial Sales. Mr. Conway
will head up the Company's global Discovery and Development
Services (DDS) business, and will retain responsibility for
corporate sales and marketing. Chris succeeds Michael A. Luther, Ph.D., MBA, who is leaving
AMRI to pursue other opportunities.
"Chris is the ideal choice to direct the next phase of AMRI's
DDS growth and development," said William
S. Marth, president and CEO, AMRI. "Chris brings deep
knowledge of AMRI's discovery and development operations and strong
commercial sales and marketing experience to the role. Since
joining AMRI in 2008, Chris has consistently demonstrated his
commercial and strategic leadership abilities generating value for
AMRI's customers while driving top and bottom line growth across
all of AMRI's business units in Discovery, Development, API, and
Drug Product. We thank Dr. Luther for his efforts in moving the DDS
business forward during the last two years and wish him the best in
his future endeavors."
Mr. Conway joined AMRI in 2008 as a Business Development Manager
with AMRI's U.S. discovery team. He was promoted to Senior Director
of the North America discovery
market in 2010 and then to Vice President of Business Development
in 2012 leading an international team of business development
managers in North America and
Europe. Chris was promoted to
Senior Vice President, Global Sales and Marketing in 2014. Before
joining AMRI, Mr. Conway held sales and leadership positions of
increasing responsibility at Johnson and Johnson and completed J&J's Commercial
Leadership Development Program.
In a related announcement, AMRI welcomes Rory Curtis, Ph.D., who joins AMRI as Vice
President of Discovery Biology and Pharmacology. Dr. Curtis, who
joins AMRI from Cubist Pharmaceuticals, will also serve as the site
head with responsibility for scientific operations at AMRI's
Buffalo, N.Y. location.
Dr. Curtis was most recently Senior Director of Human Diseases
in Discovery at Cubist Pharmaceuticals, where he developed Cubist's
antibacterial drug discovery into new disease areas such as pain,
inflammation and gastro-intestinal disease. Prior to that, he was
Senior Director of Research at Elixir Pharmaceuticals, where he
built a drug discovery platform developing small molecules to
target diseases of aging. Prior to that, Dr. Curtis held positions
of increasing responsibility at Millennium Pharmaceuticals, focused
on the discovery of novel genes as drug targets and developing
high-throughput screens. Dr. Curtis began his career at Regeneron
Pharmaceuticals developing neurotrophic factors for the treatment
of neurodegenerative disease. Dr. Curtis earned his Ph.D. in
Biochemistry from Imperial College of Science, Technology and
Medicine (University of London,
UK). He also earned his B.Sc. in Zoology from Imperial
College.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Solutions (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS
segment provides comprehensive services from hit identification to
IND, including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug metabolism and
pharmacokinetics, as well as natural products. API supports the
chemical development and cGMP manufacture of complex API, including
potent, controlled substances, biologics, peptides, steroids,
hormones, cytotoxic compounds and sterile API. DPM supports
development through commercial scale production of complex
liquid-filled and lyophilized parenterals, sterile suspensions and
ophthalmic formulations. For more information about AMRI, please
visit our website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-appoints-christopher-conway-to-lead-amri-global-discovery-and-development-services-business-names-vice-president-of-discovery-biology-and-pharmacology-300137472.html
SOURCE AMRI